Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

James McDevitt, Head of Equity Sales & Trading at Roberts & Ryan, Inc., is selected by Irish America Magazine for its 26th Annual Wall Street 50

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned Broker Dealer, is proud to recognize James McDevitt for his selection to Irish America Magazine’s 26th Annual Wall Street 50. The magazine’s Wall Street 50 recognizes the outstanding accomplishments and success of the best and the brightest Irish American and Irish-born leaders of the financial industry. Mr. McDevitt will be honored at the magazine’s gala dinner on Monday, October 30, 2023, at The New York Yacht Club. Jim’s Irish heritage can be traced back to both sets of Grandparents who emigrated to the United States in the late 1920’s. The McDevitt side from County Derry, and the maternal side from County Clare. Ireland and all things Irish have always been highlighted at family events, the history, and the luck that found the family in NYC. Mr. McDevitt is head of Equities Sales & Trading, Capital Markets at Roberts & Ryan, Inc., with an expertise in equity trading. He is a graduate of Oneota State College in New York, where he received his Bachelor of Arts degree, with a focus on American History. He also studied Technical Analysis at the New York Institute of Finance. Jim was a specialist on the floor of the New York Stock Exchange (NYSE) for 25 years, rising to become a partner at MJ Meehan & Co, and then as a Senior Vice President with Bank of America Specialists. During his career, Jim managed the trading post for marquee NYSE listed securities including Citibank, Walmart, Colgate, Sprint, McDonald’s, and JP Morgan. Jim spent three years at Academy Securities as a Managing Director selling fixed income and equity services to Corporate Treasurers. Jim has been involved in a number of charities and is a Board Member of Roberts & Ryan, Inc. He resides in Long Branch, NJ with his wife Nancy. They have three children, Patrick, Jennifer, and Colin. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker dealer providing services in debt and equity capital markets, equity and fixed-income secondary trading, as well as corporate access events. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations since 2018, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of veterans and their families, focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

October 27, 2023 09:00 AM Eastern Daylight Time

News Release

Zynex makes Healthcare Technology Report’s Top 100 healthcare tech companies for 2nd straight year

Zynex Medical

Zynex Inc Founder and CEO Thomas Sandgaard joined Steve Darling from Proactive to share news the company has been recognized as one of the Top 100 Healthcare Technology Companies of 2023 by The Healthcare Technology Report. Zynex secured the 23rd spot on the list, marking its second consecutive appearance in the top 100. Sandgaard says this is the second year in a row that Zynex has received recognition in The Healthcare Technology Report's top 100 list. In the previous year, the company was ranked 33rd. Zynex's consistent presence on this prestigious list underscores its ongoing commitment to innovation and excellence in healthcare technology. The company has a focus on pain management and hospital monitoring products. While both divisions are important, the company's primary revenue source lies in pain management, where they've maintained a successful business model for 27 years. Their pain management therapies are side-effect-free and covered by insurance companies, leading to impressive annual revenues, expected to exceed $200 million in the near future. The profitability of the pain management division enables Zynex to fund the development of products in the monitoring division. This financial strength and product diversity attract various types of investors, both retail and institutional. Zynex's recent financial performance has been outstanding, with consistent growth and successful quarterly results, continually surpassing analyst estimates. Zynex's future growth primarily hinges on its pain management division, with significant revenue expected in the coming years. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 26, 2023 02:33 PM Eastern Daylight Time

Video

News Release

Ondine Biomedical’s Steriwave nasal photodisinfection platform now used across Canada

Ondine Biomedical Inc

Ondine Biomedical Inc president and chief technology officer Nicolas Loebel joined Steve Darling from Proactive to share news the company’s Steriwave technology is being implemented at the Queen Elizabeth II Health Sciences Centre in Halifax which is a significant development for infection prevention in orthopedic surgery. The Queen Elizabeth II Health Sciences Centre in Halifax, affiliated with Dalhousie University, has adopted Steriwave, Ondine Biomedical's infection prevention method, for use in orthopedic surgeries. This technology is designed to reduce the risk of post-surgical infections, a critical concern in healthcare settings. The company's research highlights its ability to combat extensively drug-resistant microbes (XDR), an alarming threat to patient safety. Ondine's platform effectively kills these microbes, creating a barrier against antimicrobial resistance. The implementation of Steriwave is particularly crucial as healthcare institutions worldwide grapple with concerns about antimicrobial resistance. The rise of drug-resistant pathogens poses a significant threat, making infection prevention and control paramount in hospitals. Steriwave is now available in hospitals across Canada, including renowned institutions like Vancouver General Hospital, the University of British Columbia, Ottawa hospitals, and the Montreal Heart Institute. This widespread adoption highlights the technology's effectiveness and the growing recognition of its role in reducing healthcare-associated infections. The statistics related to healthcare-associated infections in Canada are concerning. One in nine hospital patients in Canada experiences a healthcare-associated infection, resulting in approximately 12,000 deaths annually. Antibiotic-resistant infections contribute significantly to this mortality rate. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 26, 2023 10:31 AM Eastern Daylight Time

Video

Kate Hudson Joins Symbiome as Creative Advisor

Symbiome

Symbiome ™, the pioneering microbiome research & development skincare brand announced today that actress and entrepreneur Kate Hudson joined the company as a Creative Advisor. As an avid Symbiome customer, Hudson will join Symbiome’s team of scientists and executives as they develop the next generation of microbiome products in consumer verticals ranging from skin to gut and oral health. Symbiome addresses the root causes of inflammatory disease in global populations, with a core mission to restore health by studying the ancestral human microbiome. With health as the primary design parameter for consumer product development, Symbiome’s eponymous skincare business is the first result of over five years of advanced microbiome research. "Kate and I are both passionate about the importance of the microbiome to our health and well-being,” says Larry Weiss, natural products chemist, Stanford-trained MD, and the CEO and Founder of Symbiome. “We are committed to developing scientifically validated products with the highest standards that help people understand and unlock the potential of the microbiome to improve their health. I am thrilled to welcome Kate to the Symbiome team” “Almost immediately after I started using Symbiome skincare, I could see and feel the difference,” says award-winning actress and entrepreneur Kate Hudson. “I am proud and excited to join the brilliant and dedicated Symbiome team on their mission to improve health from the outside in. I look forward to a future where the products that we love also nourish our microbiome, enhancing our beauty and our health.” About Symbiome. Weiss Bioscience, Inc. is a San Francisco-based microbiome biotechnology company focusing on health and wellness and the developer of the Symbiome ® brand of BioIntact ® fermented skincare products. Weiss Bioscience has sponsored three international academic research expeditions deep into the Amazon rainforest, defining an evolutionary reference point for the human microbiome and transforming our understanding of the healthy microbiome. Symbiome scientists have translated this groundbreaking research into a unique line of proprietary skincare products formulated with naturally fermented Amazonian botanicals to restore what has been lost in the modern world. Symbiome’s skincare lineup includes ten clean, organic, sustainable, and traceable products, all with less than eight ingredients. Learn more about Symbiome, and follow Symbiome on Instagram, LinkedIn, and Facebook. Contact Details BPCM Archita Patel +1 281-725-2121 archita@bpcm.com Company Website https://www.symbiome.com

October 25, 2023 12:00 PM Eastern Daylight Time

xCures Partners with the Pancreatic Cancer Action Network (PanCAN)

xCures

xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN). As part of the agreement, PanCAN's researchers and grantees will have unparalleled access to xCures' deidentified Real-time, Regulatory-grade Clinical data. This collaboration aims to drive innovations and breakthroughs in pancreatic cancer research by harnessing the power of real-time patient data. xCures database boasts fully longitudinal clinical data from thousands of pancreatic cancer patients, including over 25,000 locations and ~4,000 medical records per patient. The benefits of this partnership extend beyond the research community. xCures is making its xINFORM patient portal available to PanCAN's leading Patient Services program. The state-of-the-art portal aggregates and centralizes patients’ medical records and structures them into a computable format and an easy-to-understand longitudinal timeline. The xINFORM portal supports patients in being matched with suitable treatments and clinical programs, obtaining invaluable second opinions. Sudheer Doss, Ph.D., Chief Business Officer of PanCAN, shared his enthusiasm for the partnership: "We're always in search of innovative ways to serve our patient community better and accelerate pancreatic cancer research. As part of the comprehensive free services we offer through our PanCAN Patient Services program, this platform can pave the way for identifying optimal treatments and ensuring that our patients receive the best care possible." The PanCAN-xCures partnership blends the strengths of both organizations to advance patient outcomes and bolster research capabilities. “We at xCures are deeply committed to placing patients at the forefront of all our endeavors,” said Mika Newton, CEO of xCures. “This new partnership with PanCan is a testament to our dedication to advancing patient-centric solutions and strengthening our bond with patient advocacy organizations. Together, we will usher in a brighter, more hopeful future for all.” About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. About PanCAN The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official “Give with Confidence” charity, indicating strong financial health, ongoing accountability and transparency. Contact Details Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

October 25, 2023 10:15 AM Eastern Daylight Time

FUZE Technology Acquires MobileQubes Expanding its chargeFUZE network in Transit, Gaming & Healthcare

Full Scope PR

Los Angeles, CA - FUZE Technology (“FUZE”), a distinguished IoT company recognized for seamlessly merging hardware and software technology, has revealed its strategic acquisition of MobileQubes, a pioneering entity in portable charger vending solutions. This acquisition marks a significant expansion of FUZE Technology's network of smart charging stations, firmly establishing it as a leading provider of out-of-home mobile charging solutions across North America. FUZE, operating under its prominent brand chargeFUZE, is already a significant player in the out-of-home mobile charging landscape. Their portfolio includes extensive partnerships with Live Nation Entertainment, Unibail-Rodamco-Westfield (URW), ASM Global, Simon Property Group, and more. FUZE also powers guest experiences for the majority of professional sports organizations in North America, spanning all five major sports leagues. Furthermore, FUZE is a prominent presence at various festivals and large flagship events nationwide, including F1, US Open, Live Nation, Insomniac and C3 events. MobileQubes, widely acknowledged for pioneering portable charger vending, has made remarkable strides in mass transit by securing partnerships with major public transit operators in the US. Their influence also extends into the casino, gaming, and healthcare industries, showcasing their exceptional prowess in portable charging solutions over the past decade and earning them recognition as the original vending solution. Co-Founders Brandon Afari and Ryan Levy expressed their enthusiasm regarding the acquisition, stating, " We are thrilled to welcome MobileQubes into the FUZE family. Their expertise in portable charging and strategic partnerships in transit and gaming perfectly align with our objectives in expanding into IoT and other hardware/software avenues, including the healthcare sector." With this strategic acquisition, FUZE Technology aims to combine its strengths with those of MobileQubes, creating synergies across large-scale distribution verticals that encompass public transit systems, digital out-of-home solutions, and now healthcare. Sean Carrigan, Co-Founder and CEO of MobileQubes, stated, " This merger is a significant step forward for MobileQubes, aligning perfectly with our vision to innovate and provide accessible mobile charging solutions to a diverse range of users, particularly in the transit and gaming sectors, as well as in healthcare." This acquisition signifies more than just a merger of two innovative companies; it represents a strategic move to connect brands and advertising, offering unprecedented opportunities for businesses to engage with consumers through the widespread deployment of mobile charging solutions in high-traffic areas, including healthcare facilities. The combined strengths of FUZE Technology and MobileQubes will undoubtedly drive future innovation and redefine the landscape of out-of-home mobile charging, encompassing various sectors, including healthcare. FUZE Technology looks forward to a future of enhanced offerings and expanded reach, continuing to revolutionize the way people stay charged on the go. Contact Details Charge Fuze Press press@chargefuze.com

October 25, 2023 09:00 AM Eastern Daylight Time

Image

National Survey Reveals Women of All Ages Cite Mental Health as Their Number One Health Concern

LevLane

LevLane Advertising, an award-winning full-service agency headquartered in Philadelphia, has released the results of its 2023 Women’s Health Concerns Survey of 400 women, ages 18+, which explores how women are approaching various aspects of their health and wellness. The survey, which was conducted by a market research provider on behalf of LevLane, paints a concerning picture, as women report deprioritizing sexual/reproductive health and almost every other aspect of their well-being, while mental health concerns take priority. This is true even in the younger age groups where sexual health is traditionally considered as a primary concern (ages 18-34). Across all ages 18+, just 6% of all women reported sexual health as their number one priority. The majority of women (53%) reported mental health as one of their top three health concerns, with 26% saying that it was their number one concern. Stress management (45%), sleep health (33%) and heart health (32%) were among the other top concerns, while reproductive/sexual health (19%), diabetes (18%), pregnancy/post-partum (11%) and menopause/perimenopause (11%) were ranked lowest overall. Women 55+ were the only age group to report something other than mental health as their top concern. That cohort reported both heart health and stress management as tied for their number one priority. “Coming out of COVID, we expected to see a bump in mental health as a concern, but we were all taken aback by just how many women across all age groups cited it as their top concern,” said Liz Weir, chief marketing officer at LevLane. “Even in younger age groups, where we would expect to see more of an emphasis on sexual and reproductive health or pregnancy and post-partum, we found that women are putting those things on the back burner to prioritize mental health.” The study is the first in a series planned by the agency. The forthcoming surveys will continue to focus on specific aspects of women’s health with the goal of better understanding the broader women’s healthcare landscape. “In their efforts to address mental health concerns, an unintended consequence could be neglecting other very critical aspects of their well-being,” said Karla Loken, DO, OBGYN, FACOOG and chief medical officer for FEMSelect. “We need to address women’s health comprehensively; neglecting one area will ultimately lead to consequences in another. Women are juggling a lot of things, and this research is signaling that women need more support, including education and awareness on promoting a balanced approach to physical, mental and emotional health.” The study also found that many women are opting out of support, with half (50%) of the respondents saying they are not seeking support for their top concern/priority and have no intention of doing so. Additional Survey Findings: - 10% of Women 18-24 reported sexual and reproductive health as a top priority - 35% of women 35-44 said mental health was their top priority - Women 18-24 were the age group most concerned with cancer as a top 3 priority - Women 35-44 were the only age group to include obesity as a top 3 priority or concern - Women in the 18-34 bracket tend to start their health journeys with online search or through friends and family - Women 34+ tend to start their health journeys with their primary care physicians (PCPs) For complete survey results, please contact Lauren Stralo below. About LevLane LevLane Advertising is a full-service independent advertising agency headquartered in Philadelphia and has been building brands people love for nearly 40 years. The award-winning agency integrates traditional creative expertise with cutting-edge digital capabilities in its menu of services, including search engine optimization (SEO), search engine marketing (SEM), programmatic media, strategy, creative and branding, media and analytics, social media, content marketing, and public relations. For more information about LevLane and its capabilities, connect with us on LinkedIn, Instagram and Facebook. Contact Details LevLane Advertising Lauren Stralo +1 484-747-0172 lweir@levlane.com Company Website https://www.levlane.com

October 24, 2023 10:00 AM Eastern Daylight Time

Image

STANFORD BLOOD CENTER OPENS NEW PERMANENT DONATION CENTER IN DUBLIN

Stanford Blood Center

Stanford Blood Center (SBC) announces the opening of a new blood donation center location on Thursday, October 26, 2023, at Fallon Plaza (3738 Fallon Road) in Dublin. A ribbon-cutting ceremony will mark the occasion at 10:00 a.m. and will be attended by Dublin Councilmembers Jean Dandy and Michael McCorriston, Pleasanton Vice-Mayor Jack Balch, Blood Center leadership, and representatives from the San Jose Earthquakes. “We’re thrilled to open a location in the Tri-Valley, bringing convenience and a sense of community to our East Bay blood donors,” says SBC Executive Director Harpreet Sandhu. “Over the last few years, SBC has seen a growing number of Alameda and Contra Costa County residents coming in to donate blood at our mobile drives. This location provides an easy way for Tri-Valley community members to make consistent donations of this life-saving gift at a day and time that works for them, while bringing a more diverse pool of blood types to our reserves.” “We currently have an urgent need for all blood types, especially type O, so now is a great time to save lives and make a lasting impact for local patients,” says Donor Services Director Renee Gipson. “Donating blood is an easy way to make a huge difference. Just one donation can save up to three lives. Where else can you have that kind of impact in under an hour?” The new SBC Tri-Valley Donor Center offers: A cozy and comfortable 1,000 square feet of donation space Four blood donation chairs and one SuperRed donation (apheresis) machine Experienced staff who guide donors through every step of the process Free parking Proximity to shops and restaurants so that donors can combine their trip with other errands Easy access from the I-580 and Dublin BART Stanford Blood Center is an independent, community blood center that collects 100% of the blood reserves for Stanford Hospitals and Clinics, the Palo Alto VA, and select Bay Area community hospitals. Independent blood centers like Stanford Blood Center collect 60% of the national blood supply. As a nod to the Livermore Wine Valley, the first 250 visitors will receive a Stanford Blood Center thermal wine mug. Appointments can be scheduled online at stanfordbloodcenter.org, via the SBC mobile app, by calling 888-723-7831 or texting 999-777. Donors should be in good health with no cold, flu, or COVID-19 symptoms. Be sure to eat well prior to donation, drink fluids, and bring a photo ID. Donors must be at least 17 years of age (or 16 with a parent or guardian’s consent). Eligibility information can be found at stanfordbloodcenter.org/eligibility or by calling 888-723-7831. About Stanford Blood Center Stanford Blood Center (SBC) is an independent, community blood center that supplies blood products and testing services to multiple Bay Area hospitals and is a recognized leader in the fields of transfusion and transplantation medicine. SBC was created at the Stanford University School of Medicine in 1978 to meet the complex transfusion and transplant needs of Stanford Health Care and Lucile Packard Children’s Hospital Stanford and provide clinical trial services and specialized blood products for researchers. Today, the center remains locally focused, serving community hospitals, patients, and donors while contributing to research and advancement that impact the world at large. More information is available at stanfordbloodcenter.org. Contact Details Liza Batallones +1 415-766-0846 stanford@landispr.com

October 24, 2023 06:00 AM Pacific Daylight Time

Image

Immunic CSO hails "great" progress with MS program

Immunic Inc

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in forms of multiple sclerosis (MS) not characterised by relapses and saying that for Immunic, the most important was the focus on biomarkers. Shortly ahead of the conference Immunic had disclosed interim data from their phase two clinical study on progressive MS, revealing a significant decrease in neurofilament light chain compared to a placebo. Additionally, the company presented data from a phase two study in Relapsing Multiple Sclerosis (RMS), indicating promising results with only a 5.8% confirmed disability worsening rate. She concludes by saying that the company's MS program is going "great" overall, and expresses optimism about the direction of the company's research, emphasising the connection between their preclinical work and promising clinical trials outcomes. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

October 24, 2023 07:51 AM Eastern Daylight Time

Video

1 ... 53 54 55 56 57 ... 231

Back